EGFR expression levels affect the mode of action of egfr-targeting monoclonal antibodies

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Derer, Stefanie ^a   Lohse, Stefan ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Antibody; Epidermal growth factor receptor; Expression levels

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR IIA; MONOCLONAL ANTIBODY; NAVELBINE; PANITUMUMAB;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DOWN REGULATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; GENETIC CODE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84886945205     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24052     Document Type: Article

References (10)

1. Peipp M, Dechant M, Valerius T. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs 2009; 1:590-9; PMID:20068398; http://dx.doi.org/10.4161/mabs.1.6.10051
2. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42; PMID:22056021; http://dx.doi.org/10.1016/S1470-2045(11)70318-7
3. Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 2012; PMID:23265711; http://dx.doi.org/10.1016/j. ejca.2012.11.018
4. Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, et al. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J Immunol 2012 189:5230-9 PMID:23100515:http://dx.doi.org/10.4049/jimmunol.1202037
5. Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S, et al. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPß-dependent suppression of EGFR expression. Neoplasia 2012; 14:190-205; PMID:22496619
6. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29:3783-90; PMID:21900113; http://dx.doi.org/10.1200/JCO.2011.34.8888
7. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010; 107:12605-10; PMID:20616015; http://dx.doi.org/10.1073/pnas.1000976107
8. Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3:584-95; PMID:22123060; http://dx.doi.org/10.4161/mabs.3.6.17955
9. Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, et al. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci 2011; 102:1761-8; PMID:21718386; http://dx.doi.org/10.1111/j.1349-7006.2011.02019.x
10. Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther 2009; 8:2147-52; PMID:19783899; http://dx.doi. org/10.4161/cbt.8.22.9765